Pharmagest Interactive
Equasens Société anonyme provides healthcare IT solutions in Europe. The company publishes software and connected solutions for pharmacies, medical-social establishments, doctors, and medical auxiliaries. It also manufactures connected electronic devices and appliances for healthcare professionals and patients. In addition, the company is financing solutions for rental properties for healthcare p… Read more
Pharmagest Interactive (0R9T) - Net Assets
Latest net assets as of June 2025: €239.27 Million EUR
Based on the latest financial reports, Pharmagest Interactive (0R9T) has net assets worth €239.27 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€410.92 Million) and total liabilities (€171.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €239.27 Million |
| % of Total Assets | 58.23% |
| Annual Growth Rate | 12.01% |
| 5-Year Change | 61.59% |
| 10-Year Change | 162.89% |
| Growth Volatility | 4.06 |
Pharmagest Interactive - Net Assets Trend (2004–2024)
This chart illustrates how Pharmagest Interactive's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharmagest Interactive (2004–2024)
The table below shows the annual net assets of Pharmagest Interactive from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €240.69 Million | +5.74% |
| 2023-12-31 | €227.63 Million | +15.67% |
| 2022-12-31 | €196.80 Million | +19.10% |
| 2021-12-31 | €165.24 Million | +10.93% |
| 2020-12-31 | €148.95 Million | +12.92% |
| 2019-12-31 | €131.91 Million | +12.70% |
| 2018-12-31 | €117.05 Million | +11.56% |
| 2017-12-31 | €104.92 Million | +1.23% |
| 2016-12-31 | €103.65 Million | +13.21% |
| 2015-12-31 | €91.56 Million | +12.07% |
| 2014-12-31 | €81.69 Million | +7.39% |
| 2013-12-31 | €76.07 Million | +13.67% |
| 2012-12-31 | €66.92 Million | +14.38% |
| 2011-12-31 | €58.51 Million | +14.62% |
| 2010-12-31 | €51.04 Million | +15.37% |
| 2009-12-31 | €44.24 Million | +14.58% |
| 2008-12-31 | €38.61 Million | +14.31% |
| 2007-12-31 | €33.78 Million | +14.13% |
| 2006-12-31 | €29.60 Million | +5.57% |
| 2005-12-31 | €28.04 Million | +12.65% |
| 2004-12-31 | €24.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmagest Interactive's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 623.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €36.23 Million | 15.65% |
| Common Stock | €3.04 Million | 1.31% |
| Other Comprehensive Income | €202.19 Million | 87.34% |
| Total Equity | €231.51 Million | 100.00% |
Pharmagest Interactive Competitors by Market Cap
The table below lists competitors of Pharmagest Interactive ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OmniAb Inc.
NASDAQ:OABI
|
$177.13 Million |
|
Shandong Huapeng Glass Co Ltd
SHG:603021
|
$177.13 Million |
|
Shengtak New Material Co Ltd
SHE:300881
|
$177.17 Million |
|
Mi Technovation Berhad
PINK:MITNF
|
$177.21 Million |
|
Xiangtan Yongda Mach Mnfg Co
SHE:001239
|
$177.08 Million |
|
Utah Medical Products Inc
NASDAQ:UTMD
|
$177.03 Million |
|
Jack In The Box Inc
NASDAQ:JACK
|
$177.01 Million |
|
Avacta Group Plc
PINK:AVCTF
|
$176.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmagest Interactive's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 219,277,000 to 231,506,000, a change of 12,229,000 (5.6%).
- Net income of 36,200,000 contributed positively to equity growth.
- Dividend payments of 18,789,000 reduced retained earnings.
- Share repurchases of 6,117,000 reduced equity.
- Other comprehensive income increased equity by 22,966,000.
- Other factors decreased equity by 22,031,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €36.20 Million | +15.64% |
| Dividends Paid | €18.79 Million | -8.12% |
| Share Repurchases | €6.12 Million | -2.64% |
| Other Comprehensive Income | €22.97 Million | +9.92% |
| Other Changes | €-22.03 Million | -9.52% |
| Total Change | €- | 5.58% |
Book Value vs Market Value Analysis
This analysis compares Pharmagest Interactive's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 23.89x to 2.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €1.48 | €35.30 | x |
| 2005-12-31 | €1.66 | €35.30 | x |
| 2006-12-31 | €1.92 | €35.30 | x |
| 2007-12-31 | €2.19 | €35.30 | x |
| 2008-12-31 | €2.50 | €35.30 | x |
| 2009-12-31 | €2.88 | €35.30 | x |
| 2010-12-31 | €3.34 | €35.30 | x |
| 2011-12-31 | €3.81 | €35.30 | x |
| 2012-12-31 | €4.38 | €35.30 | x |
| 2013-12-31 | €4.99 | €35.30 | x |
| 2014-12-31 | €5.36 | €35.30 | x |
| 2015-12-31 | €5.97 | €35.30 | x |
| 2016-12-31 | €6.72 | €35.30 | x |
| 2017-12-31 | €6.75 | €35.30 | x |
| 2018-12-31 | €7.50 | €35.30 | x |
| 2019-12-31 | €8.49 | €35.30 | x |
| 2020-12-31 | €9.51 | €35.30 | x |
| 2021-12-31 | €10.48 | €35.30 | x |
| 2022-12-31 | €12.51 | €35.30 | x |
| 2023-12-31 | €14.45 | €35.30 | x |
| 2024-12-31 | €15.26 | €35.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmagest Interactive utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.64%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.70%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.72x
- Recent ROE (15.64%) is below the historical average (19.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 22.35% | 8.26% | 1.19x | 2.28x | €2.77 Million |
| 2005 | 22.51% | 8.92% | 1.14x | 2.21x | €3.15 Million |
| 2006 | 25.04% | 10.84% | 1.01x | 2.29x | €4.39 Million |
| 2007 | -25.73% | -12.06% | 1.01x | 2.11x | €-11.88 Million |
| 2008 | 23.98% | 12.17% | 0.95x | 2.07x | €5.31 Million |
| 2009 | 22.02% | 11.77% | 1.02x | 1.84x | €5.25 Million |
| 2010 | 21.77% | 12.06% | 1.08x | 1.67x | €5.97 Million |
| 2011 | 20.36% | 12.11% | 1.07x | 1.57x | €5.98 Million |
| 2012 | 20.33% | 12.43% | 1.07x | 1.53x | €6.87 Million |
| 2013 | 20.92% | 13.95% | 1.04x | 1.45x | €8.26 Million |
| 2014 | 20.91% | 14.85% | 1.01x | 1.40x | €8.88 Million |
| 2015 | 20.73% | 16.56% | 0.92x | 1.37x | €9.73 Million |
| 2016 | 20.17% | 16.02% | 0.85x | 1.48x | €10.37 Million |
| 2017 | 22.58% | 17.84% | 0.73x | 1.74x | €12.89 Million |
| 2018 | 22.34% | 17.13% | 0.66x | 1.97x | €14.05 Million |
| 2019 | 22.26% | 17.91% | 0.61x | 2.02x | €15.64 Million |
| 2020 | 21.44% | 17.88% | 0.58x | 2.06x | €16.39 Million |
| 2021 | 24.60% | 20.26% | 0.59x | 2.08x | €23.22 Million |
| 2022 | 24.44% | 21.66% | 0.61x | 1.85x | €27.40 Million |
| 2023 | 21.46% | 21.41% | 0.56x | 1.80x | €25.12 Million |
| 2024 | 15.64% | 16.70% | 0.54x | 1.72x | €13.05 Million |
Industry Comparison
This section compares Pharmagest Interactive's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmagest Interactive (0R9T) | €239.27 Million | 22.35% | 0.72x | $177.12 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |